Abstract
5/2020
vol. 37
Special paper
Biological drugs in the treatment of atopic dermatitis – current recommendations of the Polish Dermatological Society, the Polish Society of Allergology, the Polish Pediatric Society and the Polish Society of Family Medicine
- Department of Dermatology, Venereology and Allergology, Medical University of Gdansk, Gdansk, Poland
- Department of Dermatology, Medical University of Warsaw, Warsaw, Poland
- Department of Dermatology, Venereology and Allergology, Medical University of Wroclaw, Wroclaw, Poland
- Department of Pediatric Pneumonology and Allergology, Medical University of Warsaw, Warsaw, Poland
- Department of Internal Medicine, Asthma and Allergy, Medical University of Lodz, Lodz, Poland
- Department of Family Medicine, Medical University of Wroclaw, Wroclaw, Poland
- Department of Pediatrics and Pediatric Oncology, Pomeranian Medical University, Szczecin, Poland
- Department of Internal Medicine, Pneumonology, Allergology and Clinical Immunology, Military Medical Institute, Warsaw, Poland
- Department of Dermatology, Pediatric and Oncological Dermatology, Medical University of Lodz, Lodz, Poland
- Department of Dermatology, Poznan University of Medical Sciences, Poznan, Poland
- Lodz, Poland Department of Dermatology and Venereology, “Ludwik Rydygier” Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University inTorun, Poland
- Department of Dermatology, Venereology and Pediatric Dermatology, Medical University of Lublin, Lublin, Poland
- Department of Dermatology, Faculty of Medicine and Health Sciences, Jan Kochanowski University, Kielce, Poland
- Department of Dermatology and Immunodermatology, Medical University of Warsaw, Warsaw, Poland
- Department of Experimental Dermatology and Cosmetology, Jagiellonian University Medical College, Krakow, Poland
Adv Dermatol Allergol 2020; XXXVII (5): 617-624
Online publish date: 2020/11/07
Atopic dermatitis (AD) is secondary to genetic, immunological and microbiological disorders as well as epidermal barrier defects, which are the main targets of therapy. The disease proceeds with periodic exacerbations. Its development and course are influenced by numerous environmental and individual factors. In recent decades, in industrialized countries, there has been a threefold increase in the incidence of AD. There is also an increasing number of cases resistant to topical treatment. Effective treatment of AD should provide control of clinical symptoms, prevent exacerbations and improve the quality of life of patients. The multifactorial etiopathogenesis and various endotypes and phenotypes of AD justify the tendency to optimize and personalize the therapy. Currently, we recommend the use of dupilumab for the treatment of patients from 12 years of age with moderate and severe atopic dermatitis, who do not respond to topical treatment.
Keywords
biological drugs, dupilumab, atopic dermatitis, therapeutic recommendations
Indexed in
Integrated with
